Inovio Pharmaceuticals, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INO research report →
Range $3 – $5
Price Chart
About the company
Inovio Pharmaceuticals, Inc. is a biotechnology firm dedicated to the research, development, and market introduction of DNA-based treatments. Its core mission is to prevent and cure illnesses associated with human papillomavirus (HPV), various types of cancer, and infectious diseases.
- CEO
- Jacqueline E. Shea
- IPO
- 1998
- Employees
- 112
- HQ
- Plymouth Meeting, PA, US
Get TickerSpark's AI analysis on INO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $121.60M
- P/E
- -2.05
- Fwd P/E
- 4.19
- PEG
- -0.01
- P/S
- 376.78
- P/B
- -4.74
- EV/EBITDA
- -1.06
- Div Yield
- 0.00%
- Gross Margin
- -401.68%
- Op Margin
- -25953.76%
- Net Margin
- -23798.90%
- ROE
- -46473.14%
- ROIC
- 291.19%
Latest fiscal year · YoY change
- Revenue
- $65.34K-70.0%
- Gross Profit
- $65.34K-70.0%
- Op Income
- $-86,822,104
- Net Income
- $-84,945,901+20.8%
- EPS
- $-1.81+54.2%
- OCF Growth
- +14.8%
- FCF Growth
- +15.0%
- 52W High
- $2.72
- 52W Low
- $0.56
- 50D MA
- $1.21
- 200D MA
- $1.26
- Beta
- 1.61
- RSI (14)
- 63
- Avg Volume
- 11.20M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Inovio moved into commercial-stage status after FDA approval of VOCERYQ, with management emphasizing a broad launch opportunity, a strong balance sheet, and a runway into late 4Q27.· November 10, 2026
- VOCERYQ received FDA Accelerated Approval for adults with recurrent respiratory papillomatosis, and management called it a platform- and company-transforming milestone.
- The company says it has roughly $80.5 million in net proceeds from a recent equity offering, plus $48.4 million in cash and $10.9 million from warrant exercises, supporting operations into late 4Q27.
- Commercial plans center on a concentrated rare-disease market: management estimates at least 25,000 adult RRP patients in the U.S. and expects broad field coverage of the main prescribers.
- The confirmatory study draft protocol is expected before year-end, with alignment on a final protocol targeted by mid-2027.
- Management plans to file for conditional marketing authorization in Europe before year-end 2026 and is seeking ex-U.S. partnerships.
Inovio did not report product revenue for the quarter. Third-quarter 2026 operating expenses were $19.8 million, down from $21.2 million in the third quarter of 2025. Net loss was $49.2 million, or $0.50 per share basic and diluted, compared with a net loss of $45.5 million, or $0.87 per share basic and diluted, in the prior-year quarter. The larger loss was mainly due to a $26.9 million non-cash loss on fair value adjustment for warrant liabilities versus $22.5 million a year earlier. Cash, cash equivalents and short-term investments were $48.4 million at quarter-end, and after the $80.5 million equity raise plus $10.9 million of warrant proceeds, management expects funding into late 4Q27. Management said the fourth quarter of 2026 operational net cash burn is expected to be approximately $21 million as commercialization ramps, and product revenues from VOCERYQ are expected to begin in 2027.
Jacqueline Shea framed the approval of VOCERYQ as a pivotal transition from development-stage to commercial-stage company and repeatedly highlighted validation of Inovio’s DNA medicine platform. Her tone was upbeat and confident, emphasizing that VOCERYQ could become the preferred first-line treatment for adults with RRP because it addresses the disease’s root cause and fits a patient-centric regimen without scoping or surgery during the dosing window. She also stressed the broader strategic impact: expanding VOCERYQ geographically, pursuing pediatric and continued-treatment opportunities, and using the approval to support future partnerships across the pipeline.
Peter Kies focused on liquidity, capital support, and the quarter’s accounting-driven loss profile. He said the company raised approximately $80.5 million net from an underwritten public offering, ended Q3 with $48.4 million in cash, cash equivalents and short-term investments, and later received $10.9 million from warrant exercises, together supporting operations into late 4Q27. He also noted expected operational net cash burn of approximately $21 million in 4Q26 as commercialization ramps, operating expenses of $19.8 million versus $21.2 million a year ago, and that the higher net loss of $49.2 million was primarily due to a $26.9 million non-cash warrant fair-value loss.
Analysts focused on launch positioning, durability, overseas expansion, and whether the approval could help the broader pipeline. Management said VOCERYQ’s differentiation is the lack of scoping/surgery during the dosing window, its tolerability, and strong efficacy, which they believe supports first-line use despite competing early launch momentum in the category. On durability, management pointed to second- and third-year data as evidence of a sustained and statistically/clinically meaningful response. They also said the U.S. launch will be self-commercialized, while ex-U.S. territories may be pursued through partnerships and conditional marketing authorization in Europe.
The bullish case from this call is that Inovio now has its first approved product, opening a near-term commercial revenue opportunity and validating its DNA medicine platform. Management believes VOCERYQ has a differentiated profile in a concentrated rare-disease market, with a patient- and physician-friendly treatment path and enough cash to reach late 4Q27 without relying on product revenue assumptions.
The main risks are that VOCERYQ is entering a niche rare-disease market where adoption, reimbursement timing, and field execution still need to be proven. The company also faces the usual accelerated-approval uncertainty because continued approval may depend on a successful confirmatory study, and the quarter’s loss was still heavily affected by warrant fair-value volatility rather than operating improvement.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 118.5%
- Shares Outstanding
- 69.09M
- Float Shares
- 81.88M
of shares held by institutions
113 13F filers
Buy/sell ratio 1.88. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for INO, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Chris JacobsHouse · NY27 | Sell | Sep 8, 20 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Fmr LLC | 16.82M | ▲ 8.36M |
| Janus Henderson Group Ltd. | 10.43M | ▲ 10.43M |
| Ra Capital Management, L.P. | 7.22M | ▲ 7.22M |
| Jupiter Topco LLC | 5.17M | ▲ 5.17M |
| Vanguard Capital Management LLC | 4.60M | ▲ 948.79K |
| Vanguard Group Inc | 3.32M | ▲ 602.71K |
| Citadel Advisors LLC | 3.13M | ▲ 2.88M |
| Two Sigma Investments, LP | 2.54M | ▲ 1.30M |
| D. E. Shaw & Co., Inc. | 2.47M | ▲ 1.12M |
| Marshall Wace, Llp | 2.28M | ▲ 2.28M |
| Renaissance Technologies LLC | 1.51M | ▲ 1.15M |
| Adar1 Capital Management, LLC | 1.44M | ▼ 699.75K |
Held by 38 ETFs
Biggest fund positions in INO by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 20, 26 | YARNO WENDY L | other | 41,800 |
| May 20, 26 | YARNO WENDY L | other | 34,200 |
| May 20, 26 | Shepard Jay | other | 41,800 |
| May 20, 26 | Shepard Jay | other | 34,200 |
| May 20, 26 | Miller Ann Calby | other | 41,800 |
| May 20, 26 | Miller Ann Calby | other | 34,200 |
| May 20, 26 | Weiner David B. | other | 41,800 |
| May 20, 26 | Weiner David B. | other | 34,200 |
| May 20, 26 | Zoth Lota S. | other | 41,800 |
| May 20, 26 | Zoth Lota S. | other | 34,200 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our INO coverage
Recent articles, reports, and earnings notes.
No research on INO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INO report →Inovio Pharmaceuticals Prepares First Product Launch After VOCERYQ FDA Approval
marketbeat.com · Nov 18
INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
prnewswire.com · Nov 18
INOVIO to Participate in Upcoming Investor Conferences
prnewswire.com · Nov 11
Inovio Pharmaceuticals Q3 Earnings Call Highlights
marketbeat.com · Nov 10
Inovio Pharmaceuticals, Inc. (INO) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 10
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
prnewswire.com · Nov 10
INOVIO Announces Pricing of Approximately $75 Million Public Offering
prnewswire.com · Nov 5
INOVIO Announces Proposed Public Offering of its Common Stock
prnewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.